Market capitalization | $51.25m |
Enterprise Value | $-47.81m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.62 |
EV/Sales (TTM) EV/Sales | -4.85 |
P/S ratio (TTM) P/S ratio | 5.20 |
P/B ratio (TTM) P/B ratio | 0.46 |
Revenue growth (TTM) Revenue growth | 146.48% |
Revenue (TTM) Revenue | $9.86m |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
3 Analysts have issued a Kronos Bio Inc forecast:
3 Analysts have issued a Kronos Bio Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 9.86 9.86 |
147%
147%
|
|
Gross Profit | 8.08 8.08 |
40,300%
40,300%
|
|
EBITDA | -78 -78 |
36%
36%
|
EBIT (Operating Income) EBIT | -80 -80 |
36%
36%
|
Net Profit | -86 -86 |
28%
28%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Kronos Bio, Inc. is a clinical-stage biopharmaceutical, which engages in the provision of discovery and development of novel cancer therapeutics products. Its pipeline includes hematologic transcription factors, small cell, prostate cancer, and MYC-driven cancers. The company was founded by Angela Koehler and Joshua Kazam in 2017 and is headquartered in Cambridge, MA.
Head office | United States |
CEO | Norbert Bischofberger |
Employees | 63 |
Founded | 2017 |
Website | www.kronosbio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.